RxDoctor Payments Data

Keriann Kordas

Adult Health · Chicago, ILNPI 1538598180

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 81.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $3,959 and has fallen 93.1% since, to $274 in 2025. Among adult health clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,794in general payments, 2019–2025

Across 17 payments — averaging $281.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$4K
  • Jazz Pharmaceuticals Inc.$328
  • Sanofi-aventis U.S. LLC$227
  • Pfizer$135
  • AstraZeneca$112
  • Bayer$76
  • plus $32 from 1 others

What the payments were for

  • Consulting fees$2,70056%
  • Travel & lodging$1,03622%
  • Food & beverage$1,05722%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,794 in reported general payments places this provider in the 90th percentile of 553 adult health providers in Illinois.

See all adult health providers in Illinois

Medicare billing

Part B allowed, 2024
$30,542
Medicare patients
78
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate46$607,873
RezurockBelumosudil Mesylate30$456,554
IdhifaEnasidenib Mesylate11$375,817
TibsovoIvosidenib15$227,912
PrevymisLetermovir20$116,540
Posaconazole44$58,737
EliquisApixaban34$19,527
Atovaquone19$10,479
Ursodiol70$5,810
Acyclovir164$2,866
Dapsone23$1,368
ValacyclovirValacyclovir Hcl14$786
Potassium Chloride28$652
Budesonide DrBudesonide18$561
Rosuvastatin Calcium20$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$3,883$607,87346 claims
Sanofi-aventis U.S. LLCRezurock$227$456,55430 claims
PfizerEliquis$135$19,52734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 553 adult health providers in Illinois.

Other adult health in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →